• Explore /
  • Poster
  • / Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

Abstract Poster

Authors

null

Johann S. De Bono

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom

Johann S. De Bono , Ugo De Giorgi , Christophe Massard , Sergio Bracarda , Ivo Kocak , Albert Font , Jose Angel Arranz Arija , Kent C. Shih , George Daniel Radavoi , Wei Yu , Wai Y. Chan , Jian Huang , Luna C. Musib , Steven Gendreau , Raymond D. Meng , Premal H Patel , Daniel J. Maslyar , Viorel Jinga

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01485861

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5017)

DOI

10.1200/JCO.2016.34.15_suppl.5017

Abstract #

5017

Poster Bd #

274

Abstract Disclosures

Similar Posters

First Author: Syed A. Hussain

First Author: Simon J. Crabb

First Author: Sumit Kumar Subudhi

First Author: Benedito A. Carneiro